Literature DB >> 22855036

Effects of tetramethylpyrazine on cardiac function and mortality rate in septic rats.

Li-Heng Guo1, Cheng Yang, Lei Wang, Quan-Fu Chen, Ya-Nan Hu, Min-Zhou Zhang.   

Abstract

OBJECTIVE: To study the effects of tetramethylpyrazine (TMP) on cardiac function and mortality rate in septic rats.
METHODS: Fifty male Sprague-Dawley rats were randomized into a sham-operation group (sham group, n=10), normal saline group (NS group, n=20), and TMP group (n=20). The rats in the NS and TMP groups underwent cecal ligation and puncture (CLP) to induce sepsis. Rats in the NS group were injected with NS (10 mL/kg) immediately after CLP and 6 h after CLP. Rats in the TMP group were injected with TMP (10 mg/kg) at the same time points. Twenty-four hours after modeling, the mortality rates were observed in each group. Cardiac function and serum concentration of tumor necrosis factor α (TNF-α) were also tested. The correlation between TNF-α and the ejection fraction (EF) was observed. Left ventricle specimens were reserved for histomorphologic study.
RESULTS: Compared with the sham group, the NS and TMP groups had decreased EF values and increased mortality rates and serum TNF-α levels (P <0.05). The TMP group had a comparatively lower mortality rate and TNF-α level and a higher EF value compared with the NS group (P <0.05). Histomorphology indicated that myocardial inflammation in the TMP group was mild compared with that in the NS group. There was a negative correlation between TNF-α level and EF value (r=-0.583,P=0.000).
CONCLUSION: TMP could reduce the mortality rate of septic rats and had certain protective effects on cardiac function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855036     DOI: 10.1007/s11655-012-1175-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  11 in total

1.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

3.  Tumor necrosis factor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction.

Authors:  Deborah L Carlson; Monte S Willis; D Jean White; Jureta W Horton; Brett P Giroir
Journal:  Crit Care Med       Date:  2005-05       Impact factor: 7.598

4.  Cardiac output and redistribution of organ blood flow in hypermetabolic sepsis.

Authors:  C H Lang; G J Bagby; J L Ferguson; J J Spitzer
Journal:  Am J Physiol       Date:  1984-03

5.  Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China.

Authors:  Baoli Cheng; Guohao Xie; ShangLong Yao; Xinmin Wu; Qulian Guo; Miaoning Gu; Qiang Fang; Qiuping Xu; Dongxin Wang; Yuhong Jin; ShiYing Yuan; Junlu Wang; Zhaohui Du; Yunbo Sun; XiangMing Fang
Journal:  Crit Care Med       Date:  2007-11       Impact factor: 7.598

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

7.  Immunodesign of experimental sepsis by cecal ligation and puncture.

Authors:  Daniel Rittirsch; Markus S Huber-Lang; Michael A Flierl; Peter A Ward
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 8.  Sepsis and the heart.

Authors:  M W Merx; C Weber
Journal:  Circulation       Date:  2007-08-14       Impact factor: 29.690

Review 9.  Molecular events in the cardiomyopathy of sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Markus S Huber-Lang; J Vidya Sarma; Peter A Ward
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

10.  Sepsis-induced myocardial depression is associated with transcriptional changes in energy metabolism and contractile related genes: a physiological and gene expression-based approach.

Authors:  Claudia C dos Santos; David J Gattas; James N Tsoporis; Lonneke Smeding; Golam Kabir; Hussain Masoom; Ali Akram; Frans Plotz; Arthur S Slutsky; Mansoor Husain; William J Sibbald; Thomas G Parker
Journal:  Crit Care Med       Date:  2010-03       Impact factor: 7.598

View more
  4 in total

1.  Ligustrazine suppresses renal NMDAR1 and caspase-3 expressions in a mouse model of sepsis-associated acute kidney injury.

Authors:  Jing Ying; Jin Wu; Yiwei Zhang; Yangyang Han; Xinger Qian; Qiuhong Yang; Yongjie Chen; Yijun Chen; Hao Zhu
Journal:  Mol Cell Biochem       Date:  2019-11-16       Impact factor: 3.396

2.  Protective effects of Jiashen Prescription () on myocardial infarction in rats.

Authors:  Ming-Jun Zhu; You-Ping Wang; Shi-Yang Xie; Wei-Hong Liu; Bin Li; Yong-Xia Wang; He Wang; Bo-Li Zhang
Journal:  Chin J Integr Med       Date:  2014-05-10       Impact factor: 1.978

3.  Tetramethylpyrazine blocks TFAM degradation and up-regulates mitochondrial DNA copy number by interacting with TFAM.

Authors:  Linhua Lan; Miaomiao Guo; Yong Ai; Fuhong Chen; Ya Zhang; Lei Xia; Dawei Huang; Lili Niu; Ying Zheng; Carolyn K Suzuki; Yihua Zhang; Yongzhang Liu; Bin Lu
Journal:  Biosci Rep       Date:  2017-05-17       Impact factor: 3.840

4.  Ligustrazine Attenuates Myocardial Injury Induced by Coronary Microembolization in Rats by Activating the PI3K/Akt Pathway.

Authors:  Qiang Su; Xiangwei Lv; Ziliang Ye
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.